Start the conversation
U.S. drug manufacturers GlaxoSmithKline plc (ADR) (NYSE: GSK) and Novartis AG (ADR) (NYSE: NVS) announce an asset swap worth more than $20 million. The deal will reshape the future of the pharmaceutical giants. GSK will sell its portfolio of cancer drugs to Novartis, and Novartis will purchase GSK's line of vaccines. In addition, the two companies will create a consumer health venture. Meanwhile, in the med-tech sector, Boston Scientific Corp. (NYSE: BSX) announced plans to purchase Endo International Plc.'s (Nasdaq: ENDP) urology portfolio for roughly $1.65 billion.